Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) EBITDA: 2020-2025

Historic EBITDA for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$1.5 million.

  • Journey Medical's EBITDA rose 47.17% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 69.50%. This contributed to the annual value of -$13.7 million for FY2024, which is 559.77% down from last year.
  • Latest data reveals that Journey Medical reported EBITDA of -$1.5 million as of Q3 2025, which was up 46.84% from -$2.9 million recorded in Q2 2025.
  • Journey Medical's EBITDA's 5-year high stood at $17.2 million during Q3 2023, with a 5-year trough of -$13.8 million in Q2 2021.
  • For the 3-year period, Journey Medical's EBITDA averaged around -$2.1 million, with its median value being -$2.9 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 5,391.21% in 2021, then spiked by 281.68% in 2023.
  • Journey Medical's EBITDA (Quarterly) stood at -$9.1 million in 2021, then decreased by 10.36% to -$10.0 million in 2022, then skyrocketed by 78.95% to -$2.1 million in 2023, then spiked by 206.18% to $2.2 million in 2024, then surged by 47.17% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, -$2.9 million for Q2 2025, and -$3.3 million during Q1 2025.